NEW YORK & VANCOUVER, British Columbia--(BUSINESS WIRE)--Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, announced today that it has established a collaboration with Canada’s national Centre for Drug Research and Development (CDRD), to develop novel immuno-oncology monoclonal antibodies and other cancer biologics. CDRD will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. The initial project will involve an immune checkpoint target that is present on cancer stem cells.
“We’re excited to work with CDRD to aggressively translate scientific discoveries into innovative therapeutic products,” said Dr. Ramy Farid, Schrödinger’s President and CEO. “This partnership is an important step forward in our efforts to extend the successes we’ve had in small molecule drug discovery to the development of novel biologics.”
Schrödinger will support hit triage, prioritization through prediction of physico-chemical liabilities, and antibody humanization. CDRD will provide a portfolio of targeted antibodies for undisclosed oncology indications, as well as accompanying key molecular and physicochemical lab measurements. The British Columbia Cancer Agency (BCCA) will also provide critical biological data for the initial cancer stem cell project.
“Schrödinger is the leader in applying in silico modeling to small molecule drug discovery, and we are excited to be a part of this unique collaboration leveraging those capabilities to speed biologics discovery,” said Gordon C. McCauley, CDRD’s President and CEO. “This collaboration also highlights our partnership with BCCA and our collaborative approaches as we work to advance groundbreaking cancer research from bench to bedside.”
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a cofounder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger’s investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.
About CDRD (The Centre for Drug Research and Development):
CDRD is Canada’s national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients. www.cdrd.ca